Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response

NCT03331562 is registered in ClinicalTrials.gov with Translational Genomics Research Institute as lead sponsor.

NCT NCT03331562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03331562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Lead sponsor
Translational Genomics Research Institute
Phase
Phase 2
Overall status
Completed
Start date
December 27, 2017
Completion date
July 10, 2020
Enrollment
24 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer, metastatic pancreatic adenocarcinoma, metastatic pancreatic cancer, pancreas adenocarcinoma, pancreatic cancer